Shanghai Allist Pharmaceuticals Co (688578) Fair Value & Analysis
Healthcare · CN · Market cap 37.4B CNY
Fair value as of: Jul 12, 2026
From 26 valuation models · updated 29 days ago
Share price −1.3% over the past month.
A strong business, but screening 29% overvalued on our models.
What matters now
- A high-quality business (quality 81/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The model range is unusually wide (¥62.25 to ¥292.77). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range ¥15.11 – ¥133.00 · fair‑value band ¥62.25 – ¥292.77 · the ¥116.99 price screens above the ¥82.57 fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Shanghai Allist Pharmaceuticals Co (688578) currently trades at ¥116.99, while our model-based Fair Value estimate is ¥82.57, implying the stock looks roughly 29.4% overvalued today. The Quality Score stands at 81/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Shanghai Allist Pharmaceuticals Co generated revenue of 5.7B CNY at a net margin of 42.6%. Revenue grew 44.2% year over year. It earns a return on equity of 36.1%. The balance sheet holds a net cash position of 587M CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥62.25 (bear case) to ¥292.77 (bull case); at ¥116.99, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 3% below its 52-week high and 48% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -29%, 688578 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥225.21) versus Asset-Based (¥9.68). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 79 · Market factors (momentum, volatility) 58
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC).
Full company description
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai Allist Pharmaceuticals Co reported revenue of ¥5.2B in FY2025 versus ¥530M in FY2021, a compound +76.7%/yr. Reported net income was ¥2.2B in FY2025, compounding +230.5%/yr from FY2021.
688578 screens 29% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 603 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Shanghai Allist Pharmaceuticals Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shanghai Allist Pharmaceuticals Co (688578) overvalued or undervalued?
What is the fair value of 688578?
What is the quality score of 688578?
What is the revenue of Shanghai Allist Pharmaceuticals Co (688578)?
What is the net profit margin of 688578?
Does Shanghai Allist Pharmaceuticals Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shanghai Allist Pharmaceuticals Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.